Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Evotec Se (EVOTF)

Evotec Se (EVOTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Evotec Enters a Drug Discovery Collaboration with Janssen AccessWire - Tue Jun 14, 2022

HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen...

EVOTF : 10.1300 (+12.81%)
EVT : 23.92 (+0.72%)
EVO : 4.87 (+3.62%)
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology AccessWire - Thu May 19, 2022

HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global biopharmaceutical...

EVOTF : 10.1300 (+12.81%)
EVT : 23.92 (+0.72%)
EVO : 4.87 (+3.62%)
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures AccessWire - Tue Apr 12, 2022

- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY...

EVOTF : 10.1300 (+12.81%)
EVO : 4.87 (+3.62%)
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb AccessWire - Fri Apr 8, 2022

- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC...

EVOTF : 10.1300 (+12.81%)
EVO : 4.87 (+3.62%)
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic AccessWire - Mon Jan 3, 2022

- EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 - EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY...

EVOTF : 10.1300 (+12.81%)
EVT : 23.92 (+0.72%)
EVO : 4.87 (+3.62%)

Barchart Exclusives

Up 121% Since May, What's Behind the Surge in this Penny Stock? Barchart - Mon Jul 22, 8:29AM CDT
BuzzFeed is a beaten-down tech stock that has gained traction in recent months as several high-profile investors have taken a stake in the media company. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot